Compare AU

Compare DRUG vs. MCCL

Compare shares and ETFs on the ASX that you can trade on Pearler.

BetaShares Global Healthcare ETF - Currency Hedged

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are DRUG and MCCL. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.

Community Stats

DRUG

MCCL

Popularity

Low

Low

Pearlers invested

64

9

Median incremental investment

$943.50

$643.50

Median investment frequency

Monthly

Monthly

Median total investment

$1,972.00

$1,742.76

Average age group

26 - 35

26 - 35


Key Summary

DRUG

MCCL

Strategy

DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars.

MCCL.AX was created on 2022-01-20 by Munro. The fund's investment portfolio concentrates primarily on theme equity. The Fund is to maximise long term capital appreciation, by investing primarily in a concentrated long-only portfolio of companies focused on decarbonisation and climate change located anywhere in the world. The Fund aims to achieve a return greater than the MSCI All Country World (Net) Index in $A (Net) over a 5 to 7 year period

Top 3 holdings

CHF - SWISS FRANC (0 %)

AUD - AUSTRALIA DOLLAR (0 %)

DKK - DANISH KRONE (0 %)

Munro Climate Change Leaders Fund Active ETF (100 %)

Top 3 industries

Other (75.53 %)

Communication Services (33.53 %)

Health Care (24.47 %)

Top 3 countries

United States (23.96 %)

Ireland (0.52 %)

France (0.00 %)

Management fee

0.57 %

0.9 %


Key Summary

DRUG

MCCL

Issuer

BetaShares

Munro

Tracking index

Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD

Asset class

ETF

ETF

Management fee

0.57 %

0.9 %

Price

$8.50

$16.92

Size

$197.947 million

N/A

10Y return

N/A

N/A

Annual distribution/ dividend yield (5Y)

1.90 %

0.06 %

Market

ASX

ASX

First listed date

08/08/2016

19/01/2022

Purchase fee

$6.50

$6.50


Community Stats

DRUG

MCCL

Popularity

Low

Low

Pearlers invested

64

9

Median incremental investment

$943.50

$643.50

Median investment frequency

Monthly

Monthly

Median total investment

$1,972.00

$1,742.76

Average age group

26 - 35

26 - 35


Pros and Cons

DRUG

MCCL

Pros

  • Higher exposure to US market

  • Lower management fee

  • Higher price growth

  • Higher distribution yield

Cons

  • Lower exposure to US market

  • Higher management fee

  • Lower price growth

  • Lower distribution yield

DRUG

MCCL

Higher exposure to US market

Lower exposure to US market

Lower management fee

Higher management fee

Higher price growth

Lower price growth

Higher distribution yield

Lower distribution yield

Home